Scarica l'app Stockscreener
1.69
10.46%
0.16
Dopo l'orario di chiusura:
1.71
0.02
+1.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Precedente Chiudi:
$1.53
Aprire:
$1.54
Volume 24 ore:
3.72M
Relative Volume:
3.21
Capitalizzazione di mercato:
$204.27M
Reddito:
$257.24M
Utile/perdita netta:
$-237.89M
Rapporto P/E:
-0.65
EPS:
-2.6
Flusso di cassa netto:
$-175.17M
1 W Prestazione:
+23.36%
1M Prestazione:
+31.01%
6M Prestazione:
+94.66%
1 anno Prestazione:
+11.92%
Intervallo 1D:
$1.52
$1.775
Intervallo di 1 settimana:
$1.3517
$1.775
Portata 52W:
$0.71
$1.89
Coherus Oncology Inc Stock (CHRS) Company Profile
Nome
Coherus Oncology Inc
Settore
Industria
Telefono
(650) 649-3530
Indirizzo
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Confronta CHRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.69 | 184.93M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-08-16 | Downgrade | UBS | Buy → Neutral |
| 2023-11-17 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2023-07-24 | Iniziato | Citigroup | Buy |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2023-03-28 | Aggiornamento | UBS | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Neutral |
| 2022-03-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Iniziato | BofA Securities | Neutral |
| 2020-04-17 | Iniziato | SunTrust | Buy |
| 2019-08-13 | Iniziato | Mizuho | Buy |
| 2019-08-02 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-02 | Reiterato | Maxim Group | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-07 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-09 | Reiterato | Maxim Group | Buy |
| 2017-08-08 | Reiterato | JP Morgan | Overweight |
| 2017-06-13 | Reiterato | Maxim Group | Buy |
| 2017-05-05 | Iniziato | BMO Capital Markets | Outperform |
| 2016-10-19 | Iniziato | Robert W. Baird | Outperform |
| 2016-09-07 | Iniziato | Maxim Group | Buy |
| 2016-07-27 | Iniziato | Citigroup | Buy |
| 2016-01-20 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
How Coherus Oncology Inc. (8C5) stock valuation compares with sectorWeekly Profit Summary & Entry Point Confirmation Alerts - ulpravda.ru
Coherus publishes data on tagmokitug antibody for cancer treatment By Investing.com - Investing.com Nigeria
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Coherus (CHRS) Reports Promising Results for Anti-CCR8 Antibody in Cancer Treatment - GuruFocus
Coherus publishes data on tagmokitug antibody for cancer treatment - Investing.com India
Coherus Oncology Introduces Tagmokitug: Promising Results from CCR8-targeting Antibody Research - Quiver Quantitative
Coherus Oncology Announces Publication in Molecular Cancer - GlobeNewswire
What analysts say about Coherus Oncology Inc 8C5 stockMarket Insider Reports & Outstanding Growth Opportunities - earlytimes.in
Will Coherus Oncology Inc 8C5 stock outperform Dow Jones2025 Market Trends & Accurate Intraday Trading Signals - moha.gov.vn
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Coherus Oncology: A Two-Pronged March With Mid-2026 Implications (CHRS) - Seeking Alpha
Coherus Oncology, Inc.(NasdaqGM: CHRS) added to NASDAQ Biotechnology Index - marketscreener.com
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Coherus Oncology (CHRS) Price Target Increased by 13.33% to 5.78 - Nasdaq
Aug Shorts: How Coherus Oncology Inc. (8C5) stock valuation compares with sectorQuarterly Portfolio Review & AI Driven Stock Price Forecasts - Улправда
CEO Moves: How Coherus Oncology Inc. (8C5) stock valuation compares with sectorMarket Weekly Review & Risk Controlled Stock Pick Alerts - Улправда
Support Test: Can Coherus Oncology Inc. (8C5) stock survive global slowdownJuly 2025 Macro Moves & Smart Swing Trading Techniques - Улправда
Will Coherus Oncology Inc. (8C5) stock deliver stable dividends2025 Dividend Review & Breakout Confirmation Alerts - Улправда
Can Coherus Oncology Inc. (8C5) stock survive global slowdownJuly 2025 Institutional & Capital Efficient Trading Techniques - Улправда
CHRS: 2026 will be pivotal with major data readouts for novel immuno-oncology therapies - TradingView — Track All Markets
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving AverageTime to Sell? - MarketBeat
Coherus Oncology Earnings Notes - Trefis
LOQTORZI plus chemotherapy shows 31-month survival benefit in cancer study - Investing.com Australia
Coherus BioSciences stock jumps after positive cancer drug survival data By Investing.com - Investing.com UK
Coherus BioSciences stock jumps after positive cancer drug survival data - Investing.com
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma - The Manila Times
Coherus Oncology (CHRS) price target decreased by 11.77% to 5.10 - MSN
Why Coherus Oncology Inc. (8C5) stock stays on top picksTrade Risk Summary & Daily Technical Forecast Reports - Newser
Why global investors buy Coherus Oncology Inc. (8C5) stockJuly 2025 Earnings & Expert Verified Movement Alerts - Newser
Does Coherus Oncology Inc. (8C5) stock trade below intrinsic valueMarket Volume Summary & Community Consensus Stock Picks - Newser
Why Coherus Oncology Inc. (8C5) stock could rally strongly2025 Trading Volume Trends & Free Safe Entry Trade Signal Reports - Newser
Can Coherus Oncology Inc. (8C5) stock sustain free cash flow2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Coherus Oncology, Inc. (NASDAQ:CHRS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - 富途牛牛
Can Coherus Oncology Inc. (8C5) stock hold up in economic slowdownTrade Risk Assessment & Fast Gain Stock Tips - Newser
How strong is Coherus Oncology Inc. (8C5) stock earnings growthAnalyst Downgrade & Safe Entry Zone Identification - Newser
Coherus Oncology (CHRS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Coherus Oncology Inc 8C5 a good long term investmentEconomic Impact on Stocks & Build Wealth Brick by Brick With Us - earlytimes.in
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Brokerages - MarketBeat
Will Coherus Oncology Inc. (8C5) stock top growth indexesJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Will Coherus Oncology Inc. (8C5) stock outperform value peersPortfolio Update Summary & High Conviction Buy Zone Alerts - newser.com
Can Coherus Oncology Inc. (8C5) stock attract analyst upgradesJuly 2025 Selloffs & Risk Managed Investment Signals - newser.com
Will Coherus Oncology Inc. (8C5) stock benefit from infrastructure billOil Prices & Technical Confirmation Trade Alerts - newser.com
How Coherus Oncology Inc. (8C5) stock reacts to Fed tighteningWeekly Trade Analysis & Consistent Growth Stock Picks - newser.com
Coherus Oncology Inc Azioni (CHRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):